MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease

Stable Coronary Artery Disease Clinical Trial

Official title:

The Clinical Application of Magnetocardiography (MCG) as a Non-invasive Diagnostic Tool for Evaluating Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06123728
• Other study ID #: GJishen
• Status: Recruiting
• Start date: April 19, 2023
• Est. completion date: April 2024

Study information

• Verified date: October 2023
• Source: Nanhai Hospital, Guangdong Provincial People's Hospital
• Contact: Wenfei He
• Phone: 13380239072
• Email: nh2y_xnk[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (MCG) in patients with stable coronary artery disease (SCAD) and compare it with coronary CTA (CCTA). Additionally, the study aims to determine the most suitable diagnostic index for MCG. The primary question it seeks to address is whether MCG or MCG combined with CCTA can be utilized to guide the clinical application of percutaneous coronary intervention (PCI) for coronary heart disease.

Description:

1. Patients aged≥18 years with stable coronary artery disease (CCTA stenosis 30%-90%) underwent sequential examinations of MCG and CCTA. The results of CCTA were assessed using CT-FFR, and the diagnostic effectiveness of MCG in evaluating myocardial ischemia was analyzed using CT-FFR as the reference standard. Simultaneously, MCG was compared to CCTA to determine the clinical value of MCG in the functional evaluation of myocardial ischemia. 2. Coronary angiography was performed in patients who met the criteria for the procedure, and revascularization was carried out based on the intraoperative situation. Patients who underwent revascularization were followed up for 1 year, with major adverse cardiovascular events (MACE) as the endpoint. The clinical value of MCG in guiding the treatment of patients with SCAD was evaluated by reviewing the proportion of coronary angiography, revascularization, and MACE in the enrolled patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 291
• Est. completion date: April 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years old.

2. Stable coronary artery disease patients with a coronary CTA stenosis degree of 30% to 90%.

3. Sign informed consent.

Exclusion Criteria:

1. Patients diagnosed with acute coronary syndrome.

2. Patients diagnosed with hypertrophic cardiomyopathy.

3. Patients diagnosed with dilated cardiomyopathy.

4. Patients with complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, and complete bundle branch block.

5. Patients with a left ventricular ejection fraction less than 50%.

6. Patients with chronic obstructive pulmonary disease, heart failure, kidney failure, or other serious diseases.

7. Pregnant women.

8. Patients with an allergy to contrast agents.

9. The study subjects who have metal grafts that interfere with magnetic cardiogram examination.

10. The study subjects who are unable to cooperate with magnetocardiogram examination and CTA.

11. Patients who have undergone coronary artery bypass grafting.

12. There are significant artifacts present in coronary CTA.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia
• Stable Coronary Artery Disease

Locations

Country	Name	City	State
China	Nanhai Hospital, Guangdong Provincial People's Hospital	Foshan	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Nanhai Hospital, Guangdong Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Consistency in comparing MCG and CT-FFR	Initially, MCG was conducted on each patient to assess the extent of myocardial ischemia using magnetic field distribution, pseudo-current density distribution, magnetic field intensity time spectrum line, and magnetic couple parameters. Simultaneously, the CT-FFR cut-off value of 0.8 was employed as the benchmark for this study. The agreement, sensitivity, specificity, and positive/negative predictive value of cardiac ischemia were compared between MCG and CT-FFR.	1 year
Secondary	Major Adverse Cardiac Events (MACE)	Firstly, we performed coronary angiography in the above patients who met the indications of coronary angiography and performed revascularization according to the intraoperative conditions. The revascularized patients were then followed up for 1 year with major adverse cardiovascular events as the endpoint. By reviewing the ratio of coronary angiography, revascularization, and incidence of MACE in enrolled patients, the value of MCG in guiding the clinical treatment of patients with stable coronary disease was evaluated.	1 year